A closer look at “Citi Says Sell Moderna After 600% Stock Surge, Citing Overhyped Valuation”, exactly as the source publishes it. Citigroup analysts are urging investors to take profits in Moderna, arguing that the biotech's revenue and earnings outlook doesn't support its lofty valuation after a staggering 600%-plus rally in the shares. The call comes as Wall Street debates whether pandemic-driven gains for mRNA vaccine makers can be sustained beyond COVID-19 boosters.
Citi's downgrade to a sell rating reflects concern that Moderna's pipeline, while promising, is too early-stage to offset an expected decline in vaccine sales as the world moves past the emergency phase of the pandemic. The analysts note that consensus forecasts for future revenue and profit fail to justify the current share price, leaving the stock vulnerable to a sharp correction if pipeline readouts disappoint or COVID demand fades faster than expected. For the complete material, the listing points back to the source inside the network.